Search Results

By The ASCO Post Staff  / Thursday, March 20, 2014 3:03 PM

Genetic Testing May Improve Selection of Women With Estrogen Receptor–Positive Breast Cancer for 10 vs 5 Years of Hormonal Therapy

Genetic analyses of results from 1,125 postmenopausal women being treated for estrogen-responsive breast cancer have shown that some of them are more likely than others to have a late recurrence of their cancer and might benefit from 10 years of hormone therapy rather than 5 years. Women who had...